Health TrialsbyHealthPanel

A Real-World Study About Anemia in Chronic Kidney Disease in China（DASHENG）

ConditionAnemia in Chronic Kidney Disease
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWei Chen

About this trial

Anemia affects the quality of life of CKD patients and increases the risk of CKD progression. we conducted a real-world study on patients with anemia in CKD to analyze the disease characteristics and treatment in Chinese patients with CKD-anemia.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

diagnosis of CKD (e.g., "%chronic kidney disease%", "%chronic nephropathy%", "%renal failure%", "%nephritis%" for complete ICD-9/10 code mapping*)

record of hemodialysis (HD) or peritoneal dialysis (PD) (refer to Attachment 2 for dialysis identification algorithms)

≥2 eGFR measurements <60 mL/min/1.73m² (calculated using CKD-EPI equation) with ≥3-month interval (excluding acute kidney injury)

Disqualifiers

Non-renal anemia due to trauma, traffic accidents, major hemorrhage, or other confirmed etiologies (e.g., acute hemorrhagic anemia, nutritional deficiency anemia, hemolytic anemia);

Diagnosis of acute kidney disease (AKD) without chronic kidney disease (CKD) comorbidity;

Incomplete critical data elements (including age, sex, or visit dates).

Trial population

Anemia in Chronic Kidney Disease

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Disease characteristics and current treatments of anemia in chronic kidney disease (CKD) patients in China.

Disease characteristics and current treatments of anemia in chronic kidney disease (CKD) patients in China will beperformed to assess the proportions of CKD primary diseases, distribution of CKD stages, baseline Hb level distribution, and proportion of anti-anemia medication usage.

Time frame
20230101-20241231
2

Incidence of Adverse Events according to CTCAE 5.0 (Safety profile of different anemia medications in CKD patients with anemia.)

An analysis will be performed to assess the safety according to CTCAE 5.0 .

Time frame
20230101-20241231

Secondary outcomes

1

Analyze the efficacy of different anemia drugs in CKD patients with anemia.

Use the hemoglobin level to analyze the efficacy of different anemia drugs in CKD patients with anemia.

Time frame
20230101-20241231
2

Explore the economic burden of anemia in CKD patients

Use the annual cost to explore the direct economic burden of anemia in CKD patients.

Time frame
20230101-20241231

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Wei Chen

Lead sponsor

First Affiliated Hospital, Sun Yat-Sen University

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: